Cargando…
Deep brain stimulation for Alzheimer's Disease: An update
BACKGROUND: Dementia is among the leading causes of severe and long-term disability worldwide, decreasing the quality of life of individuals and families. Moreover, it induces an enormous economic burden on societies. The most prevalent cause of dementia is Alzheimer's disease (AD). Because cur...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858049/ https://www.ncbi.nlm.nih.gov/pubmed/29576909 http://dx.doi.org/10.4103/sni.sni_342_17 |
_version_ | 1783307580805742592 |
---|---|
author | Aldehri, Majed Temel, Yasin Alnaami, Ibrahim Jahanshahi, Ali Hescham, Sarah |
author_facet | Aldehri, Majed Temel, Yasin Alnaami, Ibrahim Jahanshahi, Ali Hescham, Sarah |
author_sort | Aldehri, Majed |
collection | PubMed |
description | BACKGROUND: Dementia is among the leading causes of severe and long-term disability worldwide, decreasing the quality of life of individuals and families. Moreover, it induces an enormous economic burden on societies. The most prevalent cause of dementia is Alzheimer's disease (AD). Because current treatment options for AD are limited, deep brain stimulation (DBS) has been considered. METHODS: The aim of this review is to survey the current understanding regarding the effects of DBS in AD and possibly shed light on the mechanisms of DBS in AD. We searched PubMed and Cochrane for various studies in English literature describing DBS in patients with AD and relevant preclinical studies. All related studies published from December 2013 to March 2017 were included in this review. RESULTS: Our understanding of the neural circuitry underlying learning and memory in both rodent models and human patients has grown over the past years and provided potential therapeutic targets for DBS such as the fornix and the nucleus basalis of Meynert. Clinical results indicate that DBS is most beneficial for patients who are in the early stages of AD. Potential mechanisms of action of DBS in AD comprise long-term structural plasticity, including hippocampal enlargement as well as enhanced neurotransmitter release. CONCLUSION: It is still premature to conclude that DBS can be used in the treatment of AD, and the field will wait for the results of ongoing and future clinical trials. |
format | Online Article Text |
id | pubmed-5858049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-58580492018-03-23 Deep brain stimulation for Alzheimer's Disease: An update Aldehri, Majed Temel, Yasin Alnaami, Ibrahim Jahanshahi, Ali Hescham, Sarah Surg Neurol Int Stereotactic: Review Article BACKGROUND: Dementia is among the leading causes of severe and long-term disability worldwide, decreasing the quality of life of individuals and families. Moreover, it induces an enormous economic burden on societies. The most prevalent cause of dementia is Alzheimer's disease (AD). Because current treatment options for AD are limited, deep brain stimulation (DBS) has been considered. METHODS: The aim of this review is to survey the current understanding regarding the effects of DBS in AD and possibly shed light on the mechanisms of DBS in AD. We searched PubMed and Cochrane for various studies in English literature describing DBS in patients with AD and relevant preclinical studies. All related studies published from December 2013 to March 2017 were included in this review. RESULTS: Our understanding of the neural circuitry underlying learning and memory in both rodent models and human patients has grown over the past years and provided potential therapeutic targets for DBS such as the fornix and the nucleus basalis of Meynert. Clinical results indicate that DBS is most beneficial for patients who are in the early stages of AD. Potential mechanisms of action of DBS in AD comprise long-term structural plasticity, including hippocampal enlargement as well as enhanced neurotransmitter release. CONCLUSION: It is still premature to conclude that DBS can be used in the treatment of AD, and the field will wait for the results of ongoing and future clinical trials. Medknow Publications & Media Pvt Ltd 2018-03-07 /pmc/articles/PMC5858049/ /pubmed/29576909 http://dx.doi.org/10.4103/sni.sni_342_17 Text en Copyright: © 2018 Surgical Neurology International http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Stereotactic: Review Article Aldehri, Majed Temel, Yasin Alnaami, Ibrahim Jahanshahi, Ali Hescham, Sarah Deep brain stimulation for Alzheimer's Disease: An update |
title | Deep brain stimulation for Alzheimer's Disease: An update |
title_full | Deep brain stimulation for Alzheimer's Disease: An update |
title_fullStr | Deep brain stimulation for Alzheimer's Disease: An update |
title_full_unstemmed | Deep brain stimulation for Alzheimer's Disease: An update |
title_short | Deep brain stimulation for Alzheimer's Disease: An update |
title_sort | deep brain stimulation for alzheimer's disease: an update |
topic | Stereotactic: Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858049/ https://www.ncbi.nlm.nih.gov/pubmed/29576909 http://dx.doi.org/10.4103/sni.sni_342_17 |
work_keys_str_mv | AT aldehrimajed deepbrainstimulationforalzheimersdiseaseanupdate AT temelyasin deepbrainstimulationforalzheimersdiseaseanupdate AT alnaamiibrahim deepbrainstimulationforalzheimersdiseaseanupdate AT jahanshahiali deepbrainstimulationforalzheimersdiseaseanupdate AT heschamsarah deepbrainstimulationforalzheimersdiseaseanupdate |